First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

BACKGROUND: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern Cooperative Oncology Group (ECOG) performance sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ready, Neal E, Audigier-Valette, Clarisse, Goldman, Jonathan W, Felip, Enriqueta, Ciuleanu, Tudor-Eliade, Rosario García Campelo, María, Jao, Kevin, Barlesi, Fabrice, Bordenave, Stéphanie, Rijavec, Erika, Urban, Laszlo, Aucoin, Jean-Sébastien, Zannori, Cristina, Vermaelen, Karim, Arén Frontera, Osvaldo, Curioni Fontecedro, Alessandra, Sánchez-Gastaldo, Amparo, Juan-Vidal, Oscar, Linardou, Helena, Poddubskaya, Elena, Spigel, David R, Ahmed, Samreen, Maio, Michele, Li, Sunney, Chang, Han, Fiore, Joseph, Acevedo, Angelic, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896179/
https://www.ncbi.nlm.nih.gov/pubmed/36725084
http://dx.doi.org/10.1136/jitc-2022-006127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896179/
https://www.ncbi.nlm.nih.gov/pubmed/36725084
http://dx.doi.org/10.1136/jitc-2022-006127

Ejemplares similares